Souhaitez-vous accéder aux communiqués récents ?

3 Next-Generation Enzyme Replacement Therapies (ERTs) Expected to Enter Clinic in Next 3 Years, Beginning in 2014 FY14 Cash Spend Guidance of $54-$59 Million — Current Cash Expected to Fund...

CRANBURY, N.J., Jan. 10, 2014 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases, today announced...

CRANBURY, N.J., Dec. 30, 2013 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, has completed a $25 million...

Callidus Biopharma Acquisition Adds Next-Generation Pompe ERT and Enzyme Technology Platform Revised Agreement with GSK Provides Global Development & Commercial Rights to Next-Generation...

Amicus Acquires Full Rights to Global Drug Development, Regulatory and Commercial Activities for Migalastat HCl GSK Retains Interest through Additional Equity Investment in Amicus, and Future...

Reiterates Full-Year 2013 Net Cash Spend Guidance of $47 Million to $53 Million Broad Strategic Update to be Provided by Year-End 2013 CRANBURY, N.J., Nov. 12, 2013 (GLOBE NEWSWIRE) -- Amicus...

CRANBURY, N.J., Sept. 26, 2013 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview at...

Speaking at Research!America National Health Research Forum with FDA Commissioner Hamburg Moderating Panel Discussion on Capitol Hill at Rare Disease Congressional Caucus Briefing Joining Rep....

CRANBURY, N.J., Sept. 10, 2013 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, has entered a...

CRANBURY, N.J., Sept. 5, 2013 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced that William D. "Chip" Baird, Chief Financial Officer, will present a corporate overview at the...